TLR7 and myeloid sarcoma: Concurrently in MS patients, a study on TLR7 showed the importance of TLR7 activation via its agonist, alongside administration of exogenous IFN-β, as a means to re-establish proper B cell immunoregulatory signalling in RRMS patients [46].